Quick Search
CAS Number: 73-78-9
EINECS: 200-803-8
Molecular Weight: 270.8 g/mol
Molecular Formula: C14H22N2O HCl
IUPAC Name:
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;hydrochloride
DESCRIPTION:
Lidocaine HCl Injection, USP is a sterile, nonpyrogenic, aqueous solution that contains a local anesthetic agent and is administered parenterally by injection.
Lidocaine HCl Injection, USP solution contains Lidocaine HCl, which is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride and has the molecular wt. 270.8.
Lidocaine HCl Injection, USP is a sterile, nonpyrogenic, isotonic solution containing sodium chloride. The pH of this solution is adjusted to approximately 6.5 (5.0 to 7.0) with sodium hydroxide and/or hydrochloric acid.
Lidocaine HCl is originally developed as a local anesthetic, also has properties as a class IB antiarrhythmic, a long-acting membrane stabilizing agent used against ventricular arrhythmia.
Lidocaine HCl is an antiarrhythmic compound.
Lidocaine HCl was synthesized by Löfgren and Lundquist in 1943, and was clinically introduced in 1948.
Lidocaine HCl remains one of the most widely used local anaesthetics.
Lidocaine HCl can be administered parenterally for a peripheral nerve block (PNB), intravenously, or applied topically at strengths of 2–4%.
The addition of epinephrine 1:200 000 to 1:100 000 slows the vascular absorption of lidocaine and prolongs its effects.
Lidocaine HCl is white and odorless crystal with bitter and numb taste.
Lidocaine HCl is easily soluble in water, ethanol and organic solvents, but insoluble in ether.
Aqueous solution in the case of acid and alkali do not break down, repeated autoclave rarely go bad.
Lidocaine HCl,2-(diethylamino)-2 ,6 -acetoxylidide monohydrochloride(Xylocaine), was conceived as a derivative of gramine(3-dimethylaminomethylindole) and introduced as a localanesthetic.
Lidocaine HCl is now being used intravenously as a standard parenteral agent for suppression of arrhythmias associated with acute myocardial infarction and cardiac surgery.
Lidocaine HCl isthe drug of choice for the parenteral treatment of premature ventricular contractions.
A local anesthetic and cardiac depressant used as an antiarrhythmia agent.
Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.
Lidocaine, also known as lignocaine and sold under the brand name Xylocaine among others, is a local anesthetic of the amino amide type.
Lidocaine HCL is also used to treat ventricular tachycardia.
When used for local anaesthesia or in nerve blocks, lidocaine typically begins working within several minutes and lasts for half an hour to three hours.
Lidocaine mixtures may also be applied directly to the skin or mucous membranes to numb the area.
Lidocaine HCL is often used mixed with a small amount of adrenaline (epinephrine) to prolong its local effects and to decrease bleeding.
If injected intravenously, Lidocaine HCL may cause cerebral effects such as confusion, changes in vision, numbness, tingling, and vomiting.
Lidocaine HCL can cause low blood pressure and an irregular heart rate.
There are concerns that injecting Lidocaine HCL into a joint can cause problems with the cartilage.
Lidocaine HCL appears to be generally safe for use in pregnancy.
A lower dose may be required in those with liver problems.
Lidocaine HCL is generally safe to use in those allergic to tetracaine or benzocaine.
Lidocaine is an antiarrhythmic medication of the class Ib type.
This means Lidocaine HCL works by blocking sodium channels and thus decreasing the rate of contractions of the heart.
When injected near nerves, the nerves cannot conduct signals to or from the brain.
Lidocaine was discovered in 1946 and went on sale in 1948.
Lidocaine HCL is on the World Health Organization's List of Essential Medicines.
Lidocaine HCL is available as a generic medication.
In 2019, it was the 219th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
Lidocaine Hcl Solution, also called viscous lidocaine, is a medication used to numb the mucous membranes of your mouth, gums, and/or throat.
Your provider may prescribe viscous lidocaine solution for you if you have mucositis from cancer treatment.
Mucositis causes sores or inflammation in your mouth, on your gums, or down your throat.
Viscous lidocaine works by blocking nerve cells in the affected area.
This causes numbness and can ease pain due to mucositis.
Lidocaine is a local anesthetic that works by causing temporary numbness/loss of feeling in the skin and mucous membranes.
Lidocaine is used topically to relieve itching, burning and pain from skin inflammations, injected as a dental anesthetic or as a local anesthetic for minor surgery.
Lidocaine HCl is water soluble.
Lidocaine HCl is found in over the counter topical medications that treat itching, minor skin wound pain, and skin irritation.
CAS Number: 73-78-9
EINECS: 200-803-8
Molecular Weight: 270.8 g/mol
Molecular Formula: C14H22N2O HCl
IUPAC Name:
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;hydrochloride
Chemical Properties of Lidocaine HCL:
Melting point: 80-82°C
storage temp: Inert atmosphere,2-8°C
EPA Substance Registry System: Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride (73-78-9)
Physical State :Solid
Solubility :Soluble in Chloroform
Storage :Store at 4° C
Molecular Weight: 270.80 g/mol
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 2
Rotatable Bond Count: 5
Exact Mass: 270.1498911
Monoisotopic Mass: 270.1498911
Topological Polar Surface Area: 32.3 Ų
Heavy Atom Count: 18
Formal Charge: 0
Complexity: 228
Isotope Atom Count: 0
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count: 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Covalently-Bonded Unit Count: 2
Compound Is Canonicalized: Yes
Melting Point: 77.5 °C
Manufacturing Process of Lidocaine HCl:
One mol of 2,6-xylidine is dissolved in 800 ml glacial acetic acid.
The mixture is cooled to 10°C, after which 1.1 mol chloracetyl chloride is added at one time.
The mixture is stirred vigorously during a few moments after which 1,000 ml half-saturated sodium acetate solution, or other buffering or alkalizing substance, is added at one time.
The reaction mixture is shaken during half an hour.
The precipitate formed which consists of ω-chloro-2,6- dimethyl-acetanilide is filtered off, washed with water and dried.
The product is sufficiently pure for further treatment.
The yield amounts to 70 to 80% of the theoretical amount.
One mole of the chloracetyl xylidide thus prepared and 2.5 to 3 mols diethyl amine are dissolved in 1,000 ml dry benzene.
The mixture is refluxed for 4 to 5 hours.
The separated diethyl amine hydrochloride is filtered off.
The benzene solution is shaken out two times with 3N hydrochloric acid, the first time with 800 ml and the second time with 400 ml acid.
To the combined acid extracts is added an approximately 30% solution of sodium hydroxide until the precipitate does not increase.
The precipitate, which sometimes is an oil, is taken up in ether.
The ether solution is dried with anhydrous potassium carbonate after which the ether is driven off. The remaining crude substance is purified by vacuum distillation.
During the distillation practically the entire quantity of the substance is carried over within a temperature interval of 1° to 2°C.
The yield approaches the theoretical amount. MP 68° to 69°C. BP 180° to 182°C at 4 mm Hg; 159° to 160°C at 2 mm Hg.
Local anesthetic and antiarrhythmic drugs:
Lidocaine HCl is a local anesthetic and antiarrhythmic drug.
Lidocaine HCl is clinically used for infiltration anesthesia, epidural anesthesia, surface anesthesia (including in the thoracoscopy or abdominal surgery for mucosal anesthesia) and nerve conduction block.
The drug can also be used for acute myocardial infarction after ventricular premature beats and ventricular tachycardia, and for digitalis poisoning, cardiac surgery and ventricular arrhythmias caused by cardiac catheterization.
But it is usually ineffective for supraventricular arrhythmias.
Lidocaine HCl is an amide local anesthetic.
After blood absorption or intravenous administration, the drug has obvious excitement and inhibition of biphasic effects for the central nervous system, and no excitement of the pioneer.
With the dose increased, the role or toxicity increased, there is an anti-convulsive effect with sub-poisoning plasma concentration;
Blood concentration of more than 5μg • ml-1 can occur convulsions.
Lidocaine HCl in low doses can promote outflow of K+ in cardiomyocytes, reduce myocardial autonomy, and has antiarrhythmic effects.
In the treatment dose, lidocaine HCl has no significant effect for the electrical activity of cardiomyocytes, atrioventricular conduction and myocardial contraction.
Increased plasma concentration may cause slowing of heart conduction, atrioventricular block, inhibition of myocardial contractility and decreased cardiac output.
Application of Lidocaine HCl:
Lidocaine HCl is characterized by strong penetration, strong dispersion, rapidly onset.
The anesthetic performance is twice that of procaine and the toxicity is1.
There is an anesthetic effect after 5 minutes treatments, and anesthesia can last 1 to 1.5 hours, 50% longer than procaine.
Lidocaine HCl is effective on the heart of the disease or arrhythmia caused by cardiac glycoside, but on the supraventricular tachycardia is poor.
Lidocaine HCl is fast and oral ineffective, with short duration, and often used as intravenous administration.
Biological Functions:
Lidocaine HCl (Xylocaine) is the most commonly used local anesthetic.
Lidocaine HCl is well tolerated, and in addition to its use in infiltration and regional nerve blocks, Lidocaine HCl is commonly used for spinal and topical anesthesia and as an antiarrhythmic agent.
Lidocaine has a more rapidly occurring, more intense, and more prolonged duration of action than does procaine.
Metabolism:
Lidocaine is metabolized by the liver with only a small amount (3%) found unchanged in urine.
The three main mechanisms of metabolism are shown below: N-de-ethylation > monoethylglycinexylidide (MEGX) > glycinexylidide Hydrolysis of glycinexylidide 5-hydroxylation of lidocaine’s benzene ring Lidocaine possesses convulsant activity.
Hepatic disease or reduced hepatic blood flow (as in congestive cardiac failure) will lower metabolic capacity.
Indications:
The drug can be used for infiltration anesthesia, epidural anesthesia, surface anesthesia and nerve conduction block
The drug can be used for acute myocardial infarction after ventricular premature beats and ventricular tachycardia, and for digitalis poisoning, cardiac surgery and ventricular arrhythmias caused by cardiac catheterization.
But it is usually ineffective for supraventricular arrhythmias.
Usage and dosage:
Surface anesthesia with solution of 2% to 5%.
Infiltration anesthesia with solution of 0.25% to 0.5%, conduction anesthesia with 2%, each injection point, horse, cattle 8 to 12 ml, sheep 3 to 4 ml.
Epidural anesthesia with 2% solution, horse, cow, 8 to 12 ml, dog, cat, 0.22 ml per kilogram of body weight.
Subcutaneous injection with 2% solution, pig, sheep, 80 ml, horse, cow, 400 ml, dog,25 ml, cat, 8.5 ml.
Treatment of arrhythmia, intravenous injection:
Per kg of dog’s body weight of the initial dose is 2 to 4 mg, followed by 25 to 75 micrograms per minute intravenous infusion;
Cat initial dose of 250 to 500 micrograms, followed by intravenous infusion of 20 micrograms per minute.
CAS Number: 73-78-9
EINECS: 200-803-8
Molecular Weight: 270.8 g/mol
Molecular Formula: C14H22N2O HCl
IUPAC Name:
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;hydrochloride
USES OF Lidocaine HCL:
Medical uses:
Local numbing agent:
The efficacy profile of lidocaine as a local anaesthetic is characterized by a rapid onset of action and intermediate duration of efficacy.
Therefore, lidocaine is suitable for infiltration, block, and surface anaesthesia.
Longer-acting substances such as bupivacaine are sometimes given preference for spinal and epidural anaesthesias; lidocaine, though, has the advantage of a rapid onset of action.
Adrenaline vasoconstricts arteries, reducing bleeding and also delaying the resorption of lidocaine, almost doubling the duration of anaesthesia.
Lidocaine is one of the most commonly used local anaesthetics in dentistry.
Lidocaine HCL can be administered in multiple ways, most often as a nerve block or infiltration, depending on the type of treatment carried out and the area of the mouth worked on.
For surface anaesthesia, several formulations can be used for endoscopies, before intubations, etc. Buffering the pH of lidocaine makes local numbing less painful.
Lidocaine drops can be used on the eyes for short ophthalmic procedures.
There is tentative evidence for topical lidocaine for neuropathic pain and skin graft donor site pain.
As a local numbing agent, Lidocaine HCL is used for the treatment of premature ejaculation.
An adhesive transdermal patch containing a 5% concentration of lidocaine in a hydrogel bandage, is approved by the US FDA for reducing nerve pain caused by shingles.
The transdermal patch is also used for pain from other causes, such as compressed nerves and persistent nerve pain after some surgeries.
Heart arrhythmia:
Lidocaine is also the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular arrhythmias (for acute myocardial infarction, digoxin poisoning, cardioversion, or cardiac catheterization) if amiodarone is not available or contraindicated.
Lidocaine should be given for this indication after defibrillation, CPR, and vasopressors have been initiated.
A routine preventive dose is no longer recommended after a myocardial infarction as the overall benefit is not convincing.
Epilepsy:
A 2013 review on treatment for neonatal seizures recommended intravenous lidocaine as a second-line treatment, if phenobarbital fails to stop seizures.
Other:
Intravenous lidocaine infusions are also used to treat chronic pain and acute surgical pain as an opiate sparing technique.
The quality of evidence for this use is poor so it is difficult to compare it to placebo or an epidural.
Inhaled lidocaine can be used as a cough suppressor acting peripherally to reduce the cough reflex. This application can be implemented as a safety and comfort measure for patients who have to be intubated, as it reduces the incidence of coughing and any tracheal damage it might cause when emerging from anaesthesia.
Lidocaine, along with ethanol, ammonia, and acetic acid, may also help in treating jellyfish stings, both numbing the affected area and preventing further nematocyst discharge.
For gastritis, drinking a viscous lidocaine formulation may help with the pain.
Clinical Pharmacology:
Clinical Use:
Lidocaine HCl is a class IB antiarrhythmicagent with a different effect on the electrophysiologicalproperties of myocardial cells from that of procainamideand quinidine.
Lidocaine HCL binds with equal affinity to the active (A)and inactive (I) Na+ ion channels.
Lidocaine HCL depresses diastolic depolarization and automaticity in the Purkinje fiber network and increases the functional refractory period relative toaction potential duration, as do procainamide and quinidine.
Lidocaine HCL differs from the latter two drugs, however, in that it doesnot decrease, and may even enhance, conduction velocity and increase membrane responsiveness to stimulation.
There are fewer data available on the subcellular mechanisms responsible for the antiarrhythmic actions of lidocaine than on the more established drug quinidine.
It has been proposed that lidocaine has little effect on membrane cation exchange of the atria.
Sodium ion entrance into ventricular cells during excitation is not influenced by lidocaine because it does not alter conduction velocity in this area.
Lidocaine HCl does depress Na+ influx during diastole, as do all other antiarrhythmic drugs, to diminish automaticity in myocardial tissue.
Lidocaine HCL also alters membrane responsiveness in Purkinje fibers, allowing increased conduction velocity and ample membrane potential at the time of excitation.
Mechanism of Action:
Lidocaine HCl stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.
Hemodynamics:
Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure.
With central neural blockade these changes may be attributable to block of autonomic fibers, a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system.
The net effect is normally a modest hypotension when the recommended dosages are not exceeded.
Pharmacokinetics and Metabolism:
Information derived from diverse formulations, concentrations and usages reveals that Lidocaine HCl is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent.
Except for intravascular administration, the highest blood levels are obtained following intercostal nerve block and the lowest after subcutaneous administration.
The plasma binding of Lidocaine HCl is dependent on drug concentration, and the fraction bound decreases with increasing concentration.
At concentrations of 1 to 4 mcg of free base per mL 60 to 80 percent of Lidocaine HCl is protein bound.
Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein.
Lidocaine HCl crosses the blood-brain and placental barriers, presumably by passive diffusion.
Lidocaine HCl is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys.
Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation.
N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide.
The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of Lidocaine HCl.
Approximately 90% of Lidocaine HCl administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged.
The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline.
The elimination half-life of Lidocaine HCl following an intravenous bolus injection is typically 1.5 to 2 hours.
Because of the rapid rate at which Lidocaine HCl is metabolized, any condition that affects liver function may alter Lidocaine HCl kinetics.
The half-life may be prolonged two-fold or more in patients with liver dysfunction.
Renal dysfunction does not affect Lidocaine HCl kinetics but may increase the accumulation of metabolites.
Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of Lidocaine HCl required to produce overt systemic effects.
Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6 mcg free base per mL.
In the rhesus monkey arterial blood levels of 18 to 21 mcg/mL have been shown to be threshold for convulsive activity.
Indications and Usage for Lidocaine:
Lidocaine HCl Injection, USP is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
CAS Number: 73-78-9
EINECS: 200-803-8
Molecular Weight: 270.8 g/mol
Molecular Formula: C14H22N2O HCl
IUPAC Name:
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;hydrochloride
SAFETY INFORMATION ABOUT LIDOCAINE HCL:
First-aid measures:
Description of necessary first-aid measures:
If inhaled:
Move the victim into fresh air.
If breathing is difficult, give oxygen.
If not breathing, give artificial respiration and consult a doctor immediately.
Do not use mouth to mouth resuscitation if the victim ingested or inhaled the chemical.
Following skin contact:
Take off contaminated clothing immediately.
Wash off with soap and plenty of water.
Consult a doctor.
Following eye contact:
Rinse with pure water for at least 15 minutes.
Consult a doctor.
Following ingestion:
Rinse mouth with water.
Do not induce vomiting.
Never give anything by mouth to an unconscious person.
Call a doctor or Poison Control Center immediately.
Fire-fighting measures
Suitable extinguishing media:
Use dry chemical, carbon dioxide or alcohol-resistant foam.
Special protective actions for fire-fighters:
Wear self-contained breathing apparatus for firefighting if necessary.
Accidental release measures:
Personal precautions, protective equipment and emergency procedures:
Avoid dust formation.
Avoid breathing mist, gas or vapours.
Avoid contacting with skin and eye.
Use personal protective equipment.
Wear chemical impermeable gloves.
Ensure adequate ventilation.
Remove all sources of ignition.
Evacuate personnel to safe areas.
Keep people away from and upwind of spill/leak.
Environmental precautions:
Prevent further spillage or leakage if it is safe to do so.
Do not let the chemical enter drains.
Discharge into the environment must be avoided.
Methods and materials for containment and cleaning up:
Collect and arrange disposal.
Keep the chemical in suitable and closed containers for disposal.
Remove all sources of ignition.
Use spark-proof tools and explosion-proof equipment.
Adhered or collected material should be promptly disposed of, in accordance with appropriate laws and regulations.
Handling and storage:
Precautions for safe handling:
Handling in a well ventilated place.
Wear suitable protective clothing.
Avoid contact with skin and eyes.
Avoid formation of dust and aerosols.
Use non-sparking tools.
Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities:
Store the container tightly closed in a dry, cool and well-ventilated place.
Store apart from foodstuff containers or incompatible materials.
Exposure controls/personal protection:
Appropriate engineering controls:
Ensure adequate ventilation.
Handle in accordance with good industrial hygiene and safety practice.
Set up emergency exits and the risk-elimination area.
Individual protection measures, such as personal protective equipment (PPE):
Eye/face protection:
Wear tightly fitting safety goggles with side-shields conforming to EN 166(EU) or NIOSH (US).
Skin protection:
Wear fire/flame resistant and impervious clothing.
Handle with gloves.
Gloves must be inspected prior to use.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it.
Respiratory protection:
If the exposure limits are exceeded, irritation or other symptoms are experienced, use a full-face respirator.
CAS Number: 73-78-9
EINECS: 200-803-8
Molecular Weight: 270.8 g/mol
Molecular Formula: C14H22N2O HCl
IUPAC Name:
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;hydrochloride
SYNONYMS OF LIDOCAINE HCL:
MeSH Entry Terms:
2-(Diethylamino)-N-(2,6-Dimethylphenyl)Acetamide
2-2EtN-2MePhAcN
Dalcaine
Lidocaine
Lidocaine Carbonate
Lidocaine Carbonate (2:1)
Lidocaine Hydrocarbonate
Lidocaine Hydrochloride
Lidocaine Monoacetate
Lidocaine Monohydrochloride
Lidocaine Monohydrochloride, Monohydrate
Lidocaine Sulfate (1:1)
Lignocaine
Octocaine
Xylesthesin
Xylocaine
Xylocitin
Xyloneural
Depositor-Supplied Synonyms:
Lidocaine hydrochloride
73-78-9
LIDOCAINE HCL
Lidothesin
Xyloneural
Lignocaine hydrochloride
Lidocaine (hydrochloride)
Lidocaton
Xylocard
UNII-EC2CNF7XFP
LIDOPEN
Xylocaine hydrochloride
Zingo
Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride
EC2CNF7XFP
Lidocaine hydrochloride anhydrous
Linocaine hydrochloride
MLS000069665
2-Diethylamino-2',6'-acetoxylidide hydrochloride
SMR000058468
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrochloride
Xylocaine (TN)
alpha-Diethylamino-2,6-acetoxylidine hydrochloride
Laryng-O-jet
omega-Diethylamino-2,6-dimethylacetanilide hydrochloride
Xilina hydrochloride
73-78-9 (HCl); 6108-05-0 (monohydrate)
Rucaina hydrochloride
Xycaine hydrochloride
Xylotox hydrochloride
Duncaine hydrochloride
Isicaine hydrochloride
Lidocain hydrochloride
Anestacon hydrochloride
Gravocain hydrochloride
Leostesin hydrochloride
Xylocitin hydrochloride
Lidothesin hydrochloride
Xylestesin hydrochloride
Glydo
LIDOCAINE VISCOUS
LTA II KIT
PEDIATRIC LTA KIT
LARYNG-O-JET KIT
Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, hydrochloride (1:1)
CHEBI:50512
NSC-757420
XYLOCAINE PRESERVATIVE FREE
SR-01000000189
EINECS 200-803-8
LARYNGOTRACHEAL ANESTHESIA KIT
XYLOCAINE 4% PRESERVATIVE FREE
XYLOCAINE 5% W/ GLUCOSE 7.5%
ALPHACAINE HYDROCHLORIDE
Lidocaine hydrochloride viscous
S 202
V 262
XYLOCAINE 1.5% W/ DEXTROSE 7.5%
Dalcaine (TN)
Prestwick_296
N-(Diethylaminoacetyl)-2,6-dimethylaniline hydrochloride
Lidoca ne hydrochloride
Lidocaine hydrochloride preservative free
Opera_ID_351
Lidocaine hydrochloride in plastic container
Lidocaine hydrochloride 0.2% in dextrose 5%
Lidocaine hydrochloride 0.4% in dextrose 5%
Lidocaine hydrochloride 5% and dextrose 7.5%
SPECTRUM1500689
CHEMBL541521
DTXSID4058782
HY-B0185A
HMS1568I21
HMS1921C22
Lidocaine hydrochloride preservative free in plastic container
Pharmakon1600-01500689
Lidocaine hydrochloride (JAN/USP)
2',6'-ACETOXYLIDIDE, 2-(DIETHYLAMINO)-, HYDROCHLORIDE
BCP30473
Lidocaine hydrochloride 0.2% in dextrose 5% in plastic container
Lidocaine hydrochloride 0.4% in dextrose 5% in plastic container
Lidocaine hydrochloride 0.8% in dextrose 5% in plastic container
Tox21_500669
CCG-39281
Lidocaine hydrochloride 0.1% and dextrose 5% in plastic container
Lidocaine hydrochloride 0.2% and dextrose 5% in plastic container
Lidocaine hydrochloride 0.4% and dextrose 5% in plastic container
Lidocaine hydrochloride 0.8% and dextrose 5% in plastic container
NSC757420
s4667
(unlabeled)Lidocaine-d6 Hydrochloride
AKOS015889456
CS-3888
LP00669
NSC 757420
SB19119
NCGC00094030-01
NCGC00094030-02
NCGC00094030-03
NCGC00094030-04
NCGC00094030-05
NCGC00261354-01
AC-11712
AS-35171
EU-0100669
Lignocaine hydrochloride pound>>Lidocaine HCl
A16132
D02086
L 5647
A837924
Q-201304
SR-01000000189-3
SR-01000000189-9
Q27122094
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;hydrochloride
2',6'-Acetoxylidide, 2-(diethylamino)-, monohydrochloride (8CI)
2-(diethylamino)-N-(2,6-dimethylphenyl)ethanamide hydrochloride
(Diethylamino)-2',6'-acetoxylidide Monohydrochloride
2-(diéthylamino)-N-(2,6-diméthylphényl)acétamide chlorhydrate
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrochloride
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide monohydrochloride
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide, hydrochloride (1:1)
2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamidhydrochlorid
2',6'-Acetoxylidide, 2-(diethylamino)-, monohydrochloride (8CI)
200-803-8 [EINECS]
2N2&1VMR B1 F1 &&HCl [WLN]
73-78-9 [RN]
Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, hydrochloride (1:1) [ACD/Index Name]
EC2CNF7XFP
LIDOCAINE HCL
Lidocaine hydrochloride [JAN] [USP]
Lidocaine hydrochloride anhydrous
lignocaine hydrochloride
N-(2,6-dimethylphenyl)-N2,N2-diethylglycinamide hydrochloride
N-(2,6-Dimethylphenyl)-N2,N2-diethylglycinamide hydrochloride (1:1) [ACD/IUPAC Name]
N-(2,6-Diméthylphényl)-N2,N2-diéthylglycinamide, chlorhydrate (1:1) [French] [ACD/IUPAC Name]
N-(2,6-Dimethylphenyl)-N2,N2-diethylglycinamidhydrochlorid (1:1) [German] [ACD/IUPAC Name]
N-(2,6-dimethylphenyl)-N2,N2-diethylglycinamide hydrochloride
XYLOCAINE HYDROCHLORIDE
[73-78-9]
1189959-13-4 [RN]
2-(diethylamino)-n-(2,6-dimethylphenyl)-acetamide hydrochloride
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide;hydrochloride
2-(DIETHYL-D10-AMINO)-N-(2,6-DIMETHYLPHENYL)ACETAMIDE HYDROCHLORIDE
2',6'-Acetoxylidide, 2-(diethylamino)-, hydrochloride
2-Diethylamino-2',6'-acetoxylidide hydrochloride
3917968 [Beilstein]
73-78-9 (HCl); 6108-05-0 (monohydrate)
acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, chloride, hydrogen salt (1:1)
Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride
Alphacaine
AN7700000
Anestacon
Anestacon hydrochloride
Dalcaine [Trade name]
DioCaine
Duncaine hydrochloride
Esracaine
Gravocain hydrochloride
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:50512
hydrogen chloride N-(2,6-dimethylphenyl)-N2,N2-diethylglycinamide (1:1:1)
HYDROGEN LIDOCAINE CHLORIDE
Irtopan
Isicaine hydrochloride
Laryng-O-jet
Leostesin hydrochloride
Lidocain hydrochloride
Lidocaine (hydrochloride)
Lidocaine hydrochloride monohydrate
Lidocaine-d10 Hydrochloride
LIDOCAINEHYDROCHLORIDE
Lidocaton
Lidopen
Lidothesin hydrochloride
Lignocaine hydrochloride;Xylocaine hydrochloride
Linocaine hydrochloride
metaclopramide hydrochloride
Metaclopromide Hydrochloride
MFCD00034865 [MDL number]
N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide hydrochloride
N-(Diethylaminoacetyl)-2,6-dimethylaniline hydrochloride
Rucaina hydrochloride
UNII:EC2CNF7XFP
UNII-EC2CNF7XFP
Xilina hydrochloride
Xycaine hydrochloride
Xylestesin hydrochloride
xylocaine mpf
Xylocitin hydrochloride
Xylotox hydrochloride
α-Diethylamino-2,6-acetoxylidine hydrochloride
ω-Diethylamino-2,6-dimethylacetanilide hydrochloride
LIGNOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE
LIDOCAINE HCL
Lidocaine hydrochloride CP2000,BP98
a-(diethylamino)-26-acetoxylidideHCl
a-(diethylamino)-26-acetoxylididehydrochloride
Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride 2-(diethylamino)-n-(2,6-dimethylphenyl)-acetamid monohydrochloride alpha-diethylamino-2,6-acetoxylidine hydrochloride anestacon hydrochloride duncaine hydrochloride
2-(Diethylamino)-N-(2,6-dimethylphenyl)-acetamide hydrochloride
6’-acetoxylidide,2-(diethylamino)-2hydrochloride
6’-acetoxylidide,2-(diethylamino)-2monohydrochloride
Acetamide,2-(diethylamino)-N-(2,6-diethylphenyl)-,monohydrochloride
Acetamide,2-(diethylamino)-N-(2,6-dimethylphenyl)-,monohydrochloride
alpha-diethylamino-2,6-acetoxylidinehydrochloride
anestaconhydrochloride
duncainehydrochloride
gravocainhydrochloride
isicainehydrochloride
leostesinhydrochloride
lidocainhydrochloride
lidothesinhydrochloride
n-(diethylaminoacetyl)-2,6-dimethylanilinehydrochloride
omega-diethylamino-2,6-dimethylacetanilidehydrochloride
rucainahydrochloride
s202
v262
xycainehydrochloride
xylestesinhydrochloride
xylocainehydrochloride
xylocard
xylocitinhydrochloride
xyloneural
xylotoxhydrochloride
Basicaina Monohydrate
Batixim Monohydrate
Dynexan Monohydrate
Heweneural Monohydrate
Licain Monohydrate
LIDOCAINE HYDROCHLORIDE ANHYDROUS USP
2-(diethylamino)-n-(2,6-dimethylphenyl)-acetamidmonohydrochloride
2-diethylamino-2’,6’-acetoxylididehydrochloride
LIONCAINEHYDROCHLORIDE
Lidociane Hydrochloride
Lidocaine HCL (BP/USP)
Lidocaie Hydrochloride
2-DIETHYLAMINO-N-(2'6'-DIMETHYLPHENYL)ACETAMIDE HCL
2-DIETHYLAMINO-N-[2,6-DIMETHYLPHENYL]ACETAMIDE HCL
ALPHA-(DIETHYLAMINO)-2',6'-ACETOXYLIDIDE HYDROCHLORIDE
A-(DIETHYLAMINO)-2 6-DIMETHYLACETANILIDE HYDROCHLORIDE
Lidocaine hcl powder
Lithium Claviate
LIDOCAINE HYDROCHLORIDE (LIGNOCAINE HYDROCHLORIDE)
Lidocaine HCl CAS 73-78-9 Pharmaceutical Raw Material Lidocaine kf-wang(at)kf-chem.com
99% Lidocaine Hydrochloride Pharmaceutical Raw Materials 73-78-9 Lidocaine HCl CAS NO.73-78-9
A-(DIETHYLAMINO)-2 6-DIMETHYLACETANILIDE H
Lidocaine hydrochloride cas 73-78-9 (skype：lisa_21819)
Lidocaine hydrochloride 2-(Diethylamino)-N-(2,6-dimethylphenyl)-acetamide hydrochloride
Coluracetam powder
Lidocainhydrochlorid
